Tuberculosis disease caused by Mycobacterium tuberculosis isolate that is resistant to one or more of the antitubercular medications.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation for drug-resistant tuberculosis is limited primarily due to the complexity of the disease and the variability in how it manifests among different individuals. Additionally, as this condition affects a smaller population, systematic clinical studies have been constrained, making it challenging to gather comprehensive data.
To navigate your care for drug-resistant tuberculosis, consider consulting an infectious disease specialist with experience in managing resistant tuberculosis cases. You may also explore participation in clinical trials, which could provide access to emerging therapies. For additional resources, the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support and information. Although no patient organizations are currently identified, engaging with healthcare providers about potential registries or studies may offer further insights into your condition.
Currently, there is one orphan drug designated for drug-resistant tuberculosis: dimethyl sulfoxide, which is in development. There are also 26 active clinical trials investigating various treatment approaches for this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=drug-resistant%20tuberculosis.
Actionable guidance for navigating care for drug-resistant tuberculosis
To navigate your care for drug-resistant tuberculosis, consider consulting an infectious disease specialist with experience in managing resistant tuberculosis cases. You may also explore participation in clinical trials, which could provide access to emerging therapies. For additional resources, the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support and information. Although no patient organizations are currently identified, engaging with healthcare providers about potential registries or studies may offer further insights into your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.